Published in Cancer Epidemiol Biomarkers Prev on January 01, 2009
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer (2010) 1.43
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
C-reactive protein, interleukin 6 and lung cancer risk: a meta-analysis. PLoS One (2012) 1.05
Interleukin-6 as a potential indicator for prevention of high-risk adenoma recurrence by dietary flavonols in the polyp prevention trial. Cancer Prev Res (Phila) (2010) 0.93
Tobacco exposure by various modes may alter proinflammatory (IL-12) and anti-inflammatory (IL-10) levels and affects the survival of prostate carcinoma patients: an explorative study in North Indian population. Biomed Res Int (2014) 0.93
Smoking and lung cancer-induced changes in N-glycosylation of blood serum proteins. Glycobiology (2012) 0.92
Neutrophilic airways inflammation in lung cancer: the role of exhaled LTB-4 and IL-8. BMC Cancer (2011) 0.91
Association of TNFα(-308), IFNγ(+874), and IL10(-1082) gene polymorphisms and the risk of non-small cell lung cancer in the population of the South Indian state of Telangana. Int J Clin Oncol (2016) 0.90
Biomarker development in the precision medicine era: lung cancer as a case study. Nat Rev Cancer (2016) 0.89
Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer. Ann Oncol (2013) 0.89
Elevated pretherapy serum IL17 in primary hepatocellular carcinoma patients correlate to increased risk of early recurrence after curative hepatectomy. PLoS One (2012) 0.87
A combined prognostic serum interleukin-8 and interleukin-6 classifier for stage 1 lung cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. J Thorac Oncol (2014) 0.87
A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Stimulation of neoplastic mouse lung cell proliferation by alveolar macrophage-derived, insulin-like growth factor-1 can be blocked by inhibiting MEK and PI3K activation. Mol Cancer (2011) 0.84
Loss of p53 attenuates the contribution of IL-6 deletion on suppressed tumor progression and extended survival in Kras-driven murine lung cancer. PLoS One (2013) 0.80
Modulation of peripheral immune responses by paclitaxel-ifosfamide-cisplatin chemotherapy in advanced non-small-cell lung cancer. J Cancer Res Clin Oncol (2013) 0.79
Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis. Oncoimmunology (2016) 0.78
Integration of multiple "OMIC" biomarkers: A precision medicine strategy for lung cancer. Lung Cancer (2016) 0.77
Cancer microenvironment, inflammation and cancer stem cells: A hypothesis for a paradigm change and new targets in cancer control. Surg Neurol Int (2015) 0.77
The stimulatory activity of plasma in patients with advanced non-small cell lung cancer requires TLR-stimulating nucleic acid immunoglobulin complexes and discriminates responsiveness to chemotherapy. Cancer Cell Int (2014) 0.75
Tissue and serum samples of patients with papillary thyroid cancer with and without benign background demonstrate different altered expression of proteins. PeerJ (2016) 0.75
Targeted blockade of TGF-β and IL-6/JAK2/STAT3 pathways inhibits lung cancer growth promoted by bone marrow-derived myofibroblasts. Sci Rep (2017) 0.75
Inflammation and cancer. Nature (2002) 53.78
Distinct role of macrophages in different tumor microenvironments. Cancer Res (2006) 9.29
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
IL-12 and IL-23: master regulators of innate and adaptive immunity. Immunol Rev (2004) 4.78
Systemic effects of smoking. Chest (2007) 3.63
Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 2.68
Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax (2000) 2.49
Epidemiology of lung cancer: looking to the future. J Clin Oncol (2005) 2.33
Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J (1996) 2.00
Cyclooxygenase-2 overexpression is a marker of poor prognosis in stage I non-small cell lung cancer. Clin Cancer Res (2001) 1.93
The role of tumor stroma in the interaction between tumor and immune system. Curr Opin Immunol (2005) 1.89
The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer (2003) 1.88
The role of cytokines in hepatocellular carcinoma. J Leukoc Biol (2006) 1.75
Single nucleotide polymorphisms in the human interleukin-1B gene affect transcription according to haplotype context. Hum Mol Genet (2006) 1.74
IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo. J Immunol (2007) 1.67
Association of cytokine polymorphic inheritance and in vitro cytokine production in anti-CD3/CD28-stimulated peripheral blood lymphocytes. Transplantation (2001) 1.62
Serum levels of interleukin 6 in patients with lung cancer. Br J Cancer (1995) 1.60
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst (2007) 1.58
Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine (1999) 1.50
Ethnicity greatly influences cytokine gene polymorphism distribution. Am J Transplant (2002) 1.48
Influence of TNFalpha gene polymorphisms on TNFalpha production and disease. Hum Immunol (2001) 1.47
The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer (2001) 1.38
Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res (2005) 1.37
Lung carcinoma in African Americans. Nat Clin Pract Oncol (2007) 1.33
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest (2000) 1.32
Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis (2003) 1.31
The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer (2004) 1.21
Frequency of cytokine polymorphisms in populations from western Europe, Africa, Asia, the Middle East and South America. Hum Immunol (2002) 1.20
Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res (1996) 1.17
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis. J Interferon Cytokine Res (2002) 1.13
Cytokine polymorphic analyses indicate ethnic differences in the allelic distribution of interleukin-2 and interleukin-6. Transplantation (2001) 1.11
Involvement of interleukin-6 in the elevation of plasma fibrinogen levels in lung cancer patients. Jpn J Clin Oncol (1998) 1.07
Less efficient g2-m checkpoint is associated with an increased risk of lung cancer in African Americans. Cancer Res (2005) 1.05
Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer. Med Oncol (2005) 1.03
Endogenous IL-12 triggers an antiangiogenic program in melanoma cells. Proc Natl Acad Sci U S A (2007) 1.03
Cytokine production of lung cancer cell lines: Correlation between their production and the inflammatory/immunological responses both in vivo and in vitro. Cancer Sci (2007) 1.01
Racial differences in selected cytokine allelic and genotypic frequencies among healthy, pregnant women in North Carolina. Cytokine (2003) 1.01
Prognostic significance of tumor necrosis factors and their receptors in nonsmall cell lung carcinoma. Cancer (1998) 0.98
Serum levels of apoptosis biomarkers, survivin and TNF-alpha in nonsmall cell lung cancer. Lung Cancer (2007) 0.95
Serum concentrations of proinflammatory cytokines in advanced non small cell lung cancer patients. J Exp Clin Cancer Res (1998) 0.92
Cytokines in patients with lung cancer. Scand J Immunol (2003) 0.90
Serum interleukin-6 levels correlate with malnutrition and survival in patients with advanced non-small cell lung cancer. Tumori (2004) 0.89
An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. Lung Cancer (2001) 0.89
Effect of recombinant monokines, lymphokines, and other agents on clonal proliferation of human lung cancer cell lines. Cancer Res (1987) 0.85
Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets. Cancer Immunol Immunother (1989) 0.83
Colony inhibitory effect of recombinant human tumor necrosis factor (rH-TNF) and/or recombinant human interferon (rH-IFN)-alpha, -beta and -gamma on human lung cancer cell lines. Jpn J Clin Oncol (1987) 0.80
Antitumor effect of recombinant human interleukin-1 beta alone and in combination with natural human tumor necrosis factor-alpha. Jpn J Cancer Res (1990) 0.79
Increased blood concentrations of interleukin-12 are associated with a longer survival in untreatable metastatic solid tumor patients: preliminary observations. Int J Biol Markers (1998) 0.76
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
The built environment and obesity. Epidemiol Rev (2007) 7.00
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis (2009) 3.40
The landscape of recombination in African Americans. Nature (2011) 3.06
Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis (2004) 3.04
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
Cigarette warning label policy alternatives and smoking-related health disparities. Am J Prev Med (2012) 2.72
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Nicotine therapy sampling to induce quit attempts among smokers unmotivated to quit: a randomized clinical trial. Arch Intern Med (2011) 2.67
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
Nonmelanoma skin cancer and risk for subsequent malignancy. J Natl Cancer Inst (2008) 2.08
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study. Am J Epidemiol (2002) 1.91
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol (2005) 1.74
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2005) 1.70
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet (2013) 1.69
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient care. J Acquir Immune Defic Syndr (2006) 1.66
Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A (2010) 1.66
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res (2012) 1.61
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst (2007) 1.58
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
p53: 25 years after its discovery. Trends Pharmacol Sci (2004) 1.49
Missing stage and grade in Maryland prostate cancer surveillance data, 1992-1997. Am J Prev Med (2006) 1.46
Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol (2009) 1.45
Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol (2003) 1.45
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res (2009) 1.44
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
Arsenic in drinking water and lung cancer: a systematic review. Environ Res (2008) 1.43
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
The efficacy and safety of multivitamin and mineral supplement use to prevent cancer and chronic disease in adults: a systematic review for a National Institutes of Health state-of-the-science conference. Ann Intern Med (2006) 1.41
A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene (2003) 1.40
WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res (2009) 1.39
Cruciferous vegetable consumption and lung cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev (2009) 1.38
Surgical resection of limited disease small cell lung cancer in the new era of platinum chemotherapy: Its time has come. J Thorac Cardiovasc Surg (2005) 1.37
Gender differences in sexual biomarkers and behaviors associated with human papillomavirus-16, -18, and -33 seroprevalence. Sex Transm Dis (2004) 1.36
Molecular pathogenesis of human hepatocellular carcinoma. Toxicology (2002) 1.35
p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene (2004) 1.33
p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res (2003) 1.32
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Carotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr (2008) 1.31
Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis (2003) 1.31